Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Nature reviews. Drug discovery

• Publication date

  2003-07-01

• Fields of study

  Medicine, Chemistry, History

• Identifiers
  DOI 10.1038/nrd1112PMID 12815379
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes.

  2004cited by this paper
• New lipid-modifying therapies

  2003cited by this paper
• How a statin might destroy a drug company

  2003cited by this paper
• Risk for myopathy with statin therapy in high-risk patients.

  2003cited by this paper
• Randomised, placebo-controlled trial

  2002cited by this paper
• Gemfibrozil greatly increases plasma concentrations of cerivastatin

  2002cited by this paper
• The liver and lovastatin.

  2002cited by this paper
• Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial.

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

  2002cited by this paper
• Two decades of progress in preventing vascular disease.

  2002cited by this paper
• Pleiotropic effects of statins and their clinical significance.

  2001cited by this paper
• Statin trials in progress: Unanswered questions

  2001cited by this paper
• Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials.

  2001cited by this paper
• Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering.

  2000cited by this paper
• Effect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials

  2000cited by this paper
• The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels

  2000cited by this paper
• A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH).

  2000cited by this paper
• Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease.

  2000cited by this paper
• PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA

  2000cited by this paper
• Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside.

  1999cited by this paper
• Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin.

  1999cited by this paper
• Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials.

  1999cited by this paper
• Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

  1998cited by this paper
• Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects (vol 316, pg 1213, 1998)

  1998cited by this paper
• Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety.

  1998cited by this paper
• Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin.

  1998cited by this paper
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

  1998cited by this paper
• Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia.

  1997cited by this paper
• 27 Hepatic responses to inhibition of HMG-CoA reductase: a comparison of atorvastatin and simvastatin

  1997cited by this paper
• Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia.

  1997cited by this paper
• Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study.

  1996cited by this paper
• Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration

  1996cited by this paper
• The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

  1996cited by this paper
• Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.

  1996cited by this paper
• [The Scandinavian Simvastatin Survival Study (4S)].

  1995cited by this paper
• Effects of treatment with lovastatin and pravastatin on daytime cognitive performance

  1995cited by this paper
• Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation.

  1995cited by this paper
• Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries.

  1995cited by this paper
• Lower patients' cholesterol now

  1995cited by this paper
• Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group.

  1995cited by this paper
• Clinical misconceptions dispelled by epidemiological research.

  1995cited by this paper
• Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).

  1995cited by this paper
• Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

  1995cited by this paper
• The Scandinavian Simvastatin Survival Study (4S)

  1995cited by this paper
• Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers.

  1994cited by this paper
• Ocular drug safety and HMG-CoA-reductase inhibitors.

  1994cited by this paper
• Comparison of effects on sleep of lovastatin and pravastatin in hypercholesterolemia.

  1994cited by this paper
• Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.

  1994cited by this paper
• Central Nervous System Effects of HMG CoA Reductase Inhibitors: Lovastatin and Pravastatin on Sleep and Cognitive Performance in Patients with Hypercholesterolemia

  1994cited by this paper
• Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)

  1994cited by this paper
• Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

  1994cited by this paper
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

  1994cited by this paper
• Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension.

  1994cited by this paper
• Prevention of coronary heart disease in clinical practice

  1994cited by this paper
• The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia.

  1993cited by this paper
• Gemfibrozil-induced myopathy

  1993cited by this paper
• Coronary Angiographic Changes with Lovastatin Therapy: The Monitored Atherosclerosis Regression Study (MARS)

  1993cited by this paper
• CHOLESTEROL LOWERING TRIALS IN THEIR EPIDEMIOLOGIC CONTEXT

  1993cited by this paper
• Lovastatin and the human lens; results of a two year study. The MSDRL Study Group.

  1993cited by this paper
• Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

  1993cited by this paper
• Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins.

  1992cited by this paper
• Should there be a moratorium on the use of cholesterol lowering drugs?

  1992cited by this paper
• Is cholesterol reduction always safe?

  1992cited by this paper
• HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies.

  1991cited by this paper
• Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia.

  1991cited by this paper
• Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin.

  1991cited by this paper
• Gemfibrozil-induced myopathy.

  1991cited by this paper
• No lens changes caused by simvastatin results from a prospective drug safety study.

  1990cited by this paper
• A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. The Lovastatin Study Group IV.

  1990cited by this paper
• Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials.

  1990cited by this paper
• Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy.

  1990cited by this paper
• A muclticenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia

  1990cited by this paper
• Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.

  1990cited by this paper
• The human lens after 48 weeks of treatment with lovastatin.

  1990cited by this paper
• The cholesterol controversy is over. Why did it take so long?

  1989cited by this paper
• Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors.

  1989cited by this paper
• Contrasting effects of lovastatin and cholestyramine on low-density lipoprotein cholesterol and 24-hour urinary mevalonate excretion in patients with heterozygous familial hypercholesterolemia.

  1989cited by this paper
• Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin.

  1988cited by this paper
• Lovastatin, an inhibitor of cholesterol synthesis, induces hydroxymethylglutaryl-coenzyme A reductase directly on membranes of expanded smooth endoplasmic reticulum in rat hepatocytes.

  1988cited by this paper
• A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. The Lovastatin Study Group III.

  1988cited by this paper
• Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study.

  1987cited by this paper
• Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits.

  1986cited by this paper
• Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. The Lovastatin Study Group II.

  1986cited by this paper
• Efficacy of mevinolin as adjuvant therapy for refractory familial hypercholesterolaemia.

  1986cited by this paper
• A receptor-mediated pathway for cholesterol homeostasis.

  1986cited by this paper
• Lowering blood cholesterol to prevent heart disease. NIH Consensus Development Conference Statement.

  1985cited by this paper
• Lowering Blood Cholesterol to Prevent Heart Disease

  1985cited by this paper
• CHOLESTEROL-LOWERING TRIAL RESULTS IN THEIR EPIDEMIOLOGIC CONTEXT

  1985cited by this paper
• Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia.

  1984cited by this paper
• The regulation of acetoacetyl-CoA synthetase activity by modulators of cholesterol synthesis in vivo and the utilization of acetoacetate for cholesterogenesis.

  1984cited by this paper
• The seven countries study: 2,289 deaths in 15 years.

  1984cited by this paper
• The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease.

  1984cited by this paper
• Clinical trials

  1984cited by this paper
• Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine.

  1983cited by this paper
• Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholeserolemia heterozygotes. 1983.

  1983cited by this paper
• Rapid and substantial lowering of human serum cholesterol by mevinolin (MK-803), an inhibitor of hydroxymethylglutaryl-coenzyme A reductase.

  1982cited by this paper
• Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers.

  1982cited by this paper
• Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. 1981.

  1981cited by this paper
• Serum cholesterol--the knave of hearts and the joker.

  1981cited by this paper

• Biologically Active Natural δ‐Lactones in Medicinal Chemistry: Structures, Bioactivities, and Synthesis

  2026cites this paper
• Natural Product-Derived Drugs: Structural Insights into Their Biological Mechanisms

  2025cites this paper
• Human γδ T Cell Function Is Impaired Upon Mevalonate Pathway Inhibition

  2025cites this paper
• Engineering chimeric PCSK9 for a vaccine against atherosclerosis

  2025cites this paper
• Isosulochrin xanthone and isosulochrin depsidone heterodimers from the endophytic fungus Colletotrichum sp. NF02092

  2025cites this paper
• Intracranial Hemorrhage in Zebrafish: An Adverse Outcome Induced by Lovastatin.

  2025cites this paper
• Structural Diversity and Bioactivities of Mangrove-Derived Fungal Polyketids (2020–2025)

  2025cites this paper
• Dual release scaffolds as a promising strategy for enhancing bone regeneration: an updated review.

  2025cites this paper
• Benchmarking progress in non-communicable diseases: a global analysis of cause-specific mortality from 2001 to 2019

  2025cites this paper
• The Deep Mining Era: Genomic, Metabolomic, and Integrative Approaches to Microbial Natural Products from 2018 to 2024

  2025cites this paper
• Les statines, des médicaments utiles ?

  2025cites this paper
• New insight into occurrence, quantification and bioactivities of lovastatin from natural resources (mushroom, red yeast rice and tea)

  2025cites this paper
• Florfenicol-induced gut microbiome dysbiosis triggers chronic disease pathways and intestinal damage in the benthic fish (Leiocassis longirostris).

  2025cites this paper
• A Causal Association Between Drug Use and Cognitive Impairment: A Two‐Sample Mendelian Randomization Study

  2025cites this paper
• Lipid-targeting antiviral strategies: current state and future perspectives.

  2025cites this paper
• Discovery of ASGR1 and HMGCR dual-target inhibitors based on supervised learning, molecular docking, molecular dynamics simulations, and biological evaluation.

  2025cites this paper
• Improving Cofactor Promiscuity of HMG-CoA Reductase from Ruegeria pomeroyi Through Rational Design

  2025cites this paper
• CHILD syndrome combined linear porokeratosis in a patient with a good response to the topical lovastatin/cholesterol ointment

  2025cites this paper
• Natural product-derived compounds in clinical trials and drug approvals.

  2025cites this paper
• Cryo-EM structures of apo and atorvastatin-bound human 3-hydroxy-3-methylglutaryl-coenzyme A reductase

  2025cites this paper
• Oral and Non-Oral Cholesterol-Lowering Drugs with PCSK9 and Other Biomolecules as Targets: Present Status and Future Prospects

  2025cites this paper
• Targeting fungal lipid synthesis for antifungal drug development and potentiation of contemporary antifungals

  2025cites this paper
• Statin induces epithelial cell death and tissue barrier damage in renal tubule on chip.

  2025cites this paper
• Comparative Evaluation of Vasorelaxant and Antiplatelet Activity of Two Plant-Derived Benzoquinones: Rapanone and Embelin

  2025cites this paper
• SÀNG LỌC CÁC CHỦNG VI NẤM Rhizopus sp. SINH TỔNG HỢP LOVASTATIN - CHẤT ỨC CHẾ ENZYM HYDROXYMETHYL GLUTARYL COENZYM A REDUCTASE- PHÂN LẬP Ở VIỆT NAM

  2025cites this paper
• Relationship between simvastatin pharmacokinetics and muscle toxicity in male mice.

  2025cites this paper
• Adenanthin exhibits anti-inflammatory effects by covalently targeting the p65 subunit in the NF-κB signaling pathway.

  2024cites this paper
• Pleurotus spp: an ultimate solution to the emerging calamities of the world

  2024cites this paper
• Genomic Discovery and Structure–Activity Exploration of a Novel Family of Enzyme-Activated Covalent Cyclin-Dependent Kinase Inhibitors

  2024cites this paper
• Catalytic undirected methylation of unactivated C(sp3)−H bonds suitable for complex molecules

  2024influential citation
• The Anti-Methanogenic Activity of Lovastatin in Batch Cultures Using Rumen Inoculum from Sheep, Goats, and Cows

  2024cites this paper
• Simvastatin, Its Antimicrobial Activity and Its Prevention of Alzheimer’s Disease

  2024cites this paper
• Filamentous Actin in the Nucleus in Triple-Negative Breast Cancer Stem Cells: A Key to Drug-Induced Nucleolar Stress and Stemness Inhibition?

  2024cites this paper
• Quality Control and Safety Assessment of Online-Purchased Food Supplements Containing Red Yeast Rice (RYR)

  2024cites this paper
• Exome-wide evidence of compound heterozygous effects across common phenotypes in the UK Biobank

  2024cites this paper
• ASGR1 is a promising target for lipid reduction in pigs with PON2 as its inhibitor

  2024cites this paper
• Association between circulatory microRNA-218 expression, serum PCSK9 levels, inflammatory markers, and monocyte subsets in coronary artery disease patients: impact of statin therapy

  2024cites this paper
• Novel approaches to improve lovastatin production in membrane gradostat bioreactor

  2024cites this paper
• Progress in approved drugs from natural product resources.

  2024cites this paper
• Preparation and characterization of pickering emulsion stabilized by lovastatin nanoparticles for vaccine adjuvants.

  2024cites this paper
• A secondary mechanism of action for triazole antifungals in Aspergillus fumigatus mediated by hmg1

  2024cites this paper
• Oxidative Stress-Induced Adverse Effects of Three Statins Following Single or Repetitive Treatments in Mice

  2024cites this paper
• Les statines : entre preuves scientifiques et perceptions des patients et des soignants

  2024cites this paper
• SPARC stabilizes ApoE to induce cholesterol-dependent invasion and sorafenib resistance in hepatocellular carcinoma.

  2024cites this paper
• Methyltransferase Domain‐Focused Genome Mining for Fungal Polyketide Synthases

  2024cites this paper
• Cellular metabolism regulates the differentiation and function of T-cell subsets

  2024cites this paper
• A systematic, updated review of Xuezhikang, a domestically developed lipid-lowering drug, in the application of cardiovascular diseases

  2024cites this paper
• Natural products ameliorating the adverse health effects by air particulate matter

  2024cites this paper
• First-class – biosynthesis of 6-MSA and bostrycoidin type I polyketides in Yarrowia lipolytica

  2024cites this paper
• Peroxisomal Localization of a Truncated HMG-CoA Reductase under Low Cholesterol Conditions

  2024cites this paper
• Estimation of lovastatin from Pleurotus species by thin layer chromatography and spectrophotometer

  2024cites this paper
• New Zosteropenillines and Pallidopenillines from the Seagrass-Derived Fungus Penicillium yezoense KMM 4679

  2024cites this paper
• Structural Elucidation and Complete NMR Spectral Assignments of Monascus Monacolin Analogs.

  2024cites this paper
• Expanding the Crystal Structure Landscape of Pravastatin Complexes: Tuning Solubility, Diffusion, and Pharmacokinetics

  2024cites this paper
• Toxicity Evaluation of Statin Group Drugs Using in Silico Methods

  2024cites this paper
• Association between statin usage and mortality outcomes in aging U.S. cancer survivors: a nationwide cohort study

  2024cites this paper
• Developing filamentous fungal chassis for natural product production.

  2024cites this paper
• Reshaping the gut microbiome and bile acid composition by Gyejibongnyeong-hwan ameliorates western diet-induced dyslipidemia.

  2023cites this paper
• Therapeutic Effects of Statins: Promising drug for Topical and Transdermal Administration.

  2023cites this paper
• Lovastatin inhibits erythroleukemia progression through KLF2-mediated suppression of MAPK/ERK signaling

  2023cites this paper
• BMI trajectories in late middle age, genetic risk, and the incident diabetes in older adults: evidence from a 26-year longitudinal study.

  2023cites this paper
• Bifunctional robots inducing targeted protein degradation.

  2023cites this paper
• Impact of porous microsponges in minimizing myotoxic side effects of simvastatin

  2023cites this paper
• Association between snus use and lipid status in Swedish men

  2023cites this paper
• Statinler Doz Bağımlı Olarak Depo-Bağımlı Ca2+ Girişini Baskılar

  2023cites this paper
• Multi-omics and pharmacological characterization of patient-derived glioma cell lines

  2023cites this paper
• Use of an Uncertainty Profile to Validate High-Performance Liquid Chromatography (HPLC) for the Simultaneous Determination of Statins in Synthetic Pharmaceutical Products

  2023cites this paper
• Simvastatin for lowering lipids

  2023cites this paper
• Highlights on U.S. FDA-approved fluorinated drugs over the past five years (2018-2022).

  2023cites this paper
• CRISPR Screens Identify Toxoplasma Genes That Determine Parasite Fitness in Interferon Gamma-Stimulated Human Cells

  2023cites this paper
• Research Progress in the Clinical Treatment of Familial Hypercholesterolemia.

  2023cites this paper
• Mechanism of the Regulation of Plasma Cholesterol Levels by PI(4,5)P2.

  2023cites this paper
• Isolation and Identification of Novel Antioxidant Polyketides from an Endophytic Fungus Ophiobolus cirsii LZU-1509.

  2023cites this paper
• Landscape of Statin as a Cornerstone in Atherosclerotic Cardiovascular Disease

  2023cites this paper
• Discovery of Natural Potent HMG-CoA Reductase Degraders for Lowering Cholesterol.

  2023cites this paper
• Linking Lichen Metabolites to Genes: Emerging Concepts and Lessons from Molecular Biology and Metagenomics

  2023cites this paper
• Evaluation of Enhanced Cytotoxicity Effect of Repurposed Drug Simvastatin/ Thymoquinone Combination against Breast Cancer Cell Line.

  2023cites this paper
• Efficacy of Poria cocos and Alismatis rhizoma against diet-induced hyperlipidemia in rats based on transcriptome sequencing analysis

  2023cites this paper
• Differential Pharmacokinetic Interplay of Atorvastatin on Lacosamide and Levetiracetam on Experimental Convulsions in Mice.

  2023cites this paper
• Oral Intake of Inosine 5′-Monophosphate in Mice Promotes the Absorption of Exogenous Fatty Acids and Their Conversion into Triglycerides though Enhancing the Phosphorylation of Adenosine 5′-Monophosphate-Activated Protein Kinase in the Liver, Leading to Lipohyperplasia

  2023cites this paper
• Pitavastatin and Lovastatin Exhibit Calcium Channel Blocking Activity Which Potentiate Vasorelaxant Effects of Amlodipine: A New Futuristic Dimension in Statin’s Pleiotropy

  2023cites this paper
• Walnut fruit diaphragm ethanol extract ameliorates damage due to Triton WR‐1339‐induced hyperlipidemia in rats

  2023cites this paper
• Using stable carbon isotope ratio analysis to detect adulteration in red yeast rice dietary supplements.

  2023cites this paper
• Lipid-based nanocarriers challenging the ocular biological barriers: Current paradigm and future perspectives.

  2023cites this paper
• Genomic Based Analysis of the Biocontrol Species Trichoderma harzianum: A Model Resource of Structurally Diverse Pharmaceuticals and Biopesticides

  2023cites this paper
• The Effects of Statins on Cognitive Performance Are Mediated by Low-Density Lipoprotein, C-Reactive Protein, and Blood Glucose Concentrations

  2023cites this paper
• Structural enzymology of iterative type I polyketide synthases: various routes to catalytic programming.

  2023cites this paper
• Multiplex metabolic pathway engineering of Monascus pilosus enhances lovastatin production

  2023cites this paper
• Recent advances in anti-inflammatory active components and action mechanisms of natural medicines

  2023cites this paper
• Ligand-enabled Ni-catalysed enantioconvergent intermolecular Alkyl-Alkyl cross-coupling between distinct Alkyl halides

  2023cites this paper
• Structure of a modular polyketide synthase reducing region.

  2023cites this paper
• Bioinformatic Analysis of Key Regulatory Genes in Adult Asthma and Prediction of Potential Drug Candidates

  2023cites this paper
• Exome-wide evidence of compound heterozygous effects across common phenotypes in the UK Biobank

  2023cites this paper
• RHOA Therapeutic Targeting in Hematological Cancers

  2023cites this paper
• Intracellularly driven chemical modifications of antimicrobial secondary metabolites: Potent mechanisms of self-resistance

  2023cites this paper
• LDL Cholesterol—How Low Can We Go?

  2023cites this paper
• The Effects of Sesamin Supplementation on Obesity, Blood Pressure, and Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2022cites this paper
• Melatonin: Regulation of Prion Protein Phase Separation in Cancer Multidrug Resistance

  2022cites this paper
• The effect of acupoint catgut embedding and drug therapy on hyperlipidemia: a meta-analysis of randomized controlled trials

  2022cites this paper
• Statins for people with intracerebral hemorrhage

  2022cites this paper